This is a Twitter summary from #ACAAI16 meeting. The post is a part of series. See the rest here: http://allergynotes.blogspot.com/search/label/#ACAAI16Several allergists did a great job posting updates on Twitter from the 2016 meeting of ACAAI, the hashtag was #ACAAI16. I used the website Symplur to review the tweets:
@choirdoc @kristinkrasnow @docalergias @drsilge
http://www.symplur.com/healthcare-hashtags/acaai16/
Presentation handouts are available from the ACAAI website: http://annualmeeting.acaai.org/session_presentations.cfm
Dupilumab may be an effective agent in minimizing nasal polyps - very difficult disease to treat with currently available medications. Dupilimab was not only studied and effective for eczema, but also for CRS with nasal polyps, as well as asthma.
@texasgregmd: Dupilumab cost would be $25,000 per year.
Budesonide 2 mg sinus rinse daily for 12 months - safe without HPA axis suppression https://t.co/s5uiJkKY7k
Off-label use of budesonide sinus rinses safe even in long-term use, though some had clinically insignificant adrenal suppression.
5% per year risk of developing asthma in chronic rhinosinusitis. Surgery may be disease-modifying.